Mark McGurk

Corporate Officer/Principal at King's College London

Consumer Services

Commercial Services

Profile

Mark McGurk is currently a Professor at King's College London.
Prior to this, he worked as a Principal at The University of Manchester and Odontis Ltd.

Mark McGurk active positions

Companies	Position	Start
King's College London	Corporate Officer/Principal	-

All active positions of Mark McGurk

Former positions of Mark McGurk

Companies	Position	End
Odontis Ltd. Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development.	Corporate Officer/Principal	18/01/2011
The University of Manchester	Corporate Officer/Principal	-

See the detail of Mark McGurk's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mark McGurk's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Odontis Ltd. Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development.	Commercial Services